Table 1.
Patient and clinical characteristics (no. of patients (%))
| All (N=45) | Pancreatic (N=19) | Gastrointestinal intestinal and unknown origin (N=17) | Others lung and paraganglioma (N=9) | |
|---|---|---|---|---|
|
Sex |
|
|
|
|
| Male |
32 (71.1) |
15 (78.9) |
9 (52.9) |
8 (88.9) |
| Female |
13 (28.9) |
4 (21.1) |
8 (47.1) |
1 (11.1) |
|
Age (yrs) |
|
|
|
|
| Median (range) |
52 (28-73) |
|
|
|
|
ECOG performance status |
|
|
|
|
| 0 |
36 (80.0) |
13 (68.4) |
17 (100) |
6 (66.7) |
| 1 |
6 (13.3) |
3 (15.8) |
-- |
3 (33.3) |
| 2 |
3 (6.7) |
3 (15.8) |
|
|
|
Ki67 index |
|
|
|
|
| ≤2 |
10 (25.6) |
2 (11.8) |
5 (33.3) |
3 (42.8) |
| 3-20 |
29 (74.4) |
15 (88.2) |
15 (66.6) |
4 (57.2) |
| Missing |
6 |
2 |
2 |
2 |
|
Octreoscan |
|
|
|
|
| Positive |
43 (95.6) |
18 (94.7) |
16 (94.1) |
9 (100) |
| Negative |
2 (4.4) |
1 (5.3) |
1 (5.9) |
|
|
Circulating chromogranin A |
|
|
|
|
| Normal |
8 |
3 (17.6) |
4 (23.5) |
1 (12.5) |
| Elevated |
34 |
14 (82.4) |
13 (76.5) |
7 (87.5) |
| Missing |
3 |
2 |
-- |
1 |
|
Sites of metastatic disease |
|
|
|
|
| Liver |
41 (91.1) |
18 (94.7) |
16 (94.1) |
7 (77.8) |
| Lymph nodes |
17 (37.8) |
6 (31.4) |
8 (47.1) |
3 (33.3) |
| Lung |
5 (11.1) |
0 (0) |
-- |
4 (44.4) |
| Bone |
2 (4.4) |
2 (10.5) |
1 (5.9) |
-- |
|
Syndrome |
17 (37.8) |
5 (26.3) |
11 (64.7) |
1 (11.1) |
| Diarrhea |
10 (22.2) |
3 (15.8) |
6 (35.3) |
1 (11.1) |
| Hot flashes |
7 (15.6) |
-- |
6 (35.3) |
1 (11.1) |
| Rash |
7 (15.6) |
-- |
6 (35.3) |
1 (11.1) |
| Hypoglycemia |
1 (2.2) |
1 (5.3) |
-- |
-- |
| Cushing’s syndrome |
1 (2.2) |
1 (5.3) |
-- |
-- |
|
Previous treatments |
|
|
|
|
| Surgery |
34 (75.6) |
13 (68.4) |
14 (82.3) |
7 (77.8) |
| Radiotherapy |
2 (4.4) |
2 (10.5) |
-- |
-- |
| Radionuclide therapy with somatostatin analogues | 23 (51.1) | 10 (43.5) | 8 (34.8) | 5 (21.7) |